These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23207620)

  • 1. Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash.
    Takashima N; Kimura T; Watanabe N; Umemura T; Katsuno S; Arakawa K; Fukatsu M; Nakamura N; Nishiyama O; Kataoka K; Kondoh Y; Taniguchi H
    Onkologie; 2012; 35(12):747-52. PubMed ID: 23207620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer.
    Zhou S; Ren S; Yan L; Zhang L; Tang L; Zhang J; Zhou C
    Respirology; 2009 Jul; 14(5):709-15. PubMed ID: 19659649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
    Matsuura S; Inui N; Ozawa Y; Nakamura Y; Toyoshima M; Yasuda K; Yamada T; Shirai T; Suganuma H; Yokomura K; Suda T; Chida K
    Jpn J Clin Oncol; 2011 Aug; 41(8):959-63. PubMed ID: 21715361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA drug approval summary: erlotinib (Tarceva) tablets.
    Cohen MH; Johnson JR; Chen YF; Sridhara R; Pazdur R
    Oncologist; 2005 Aug; 10(7):461-6. PubMed ID: 16079312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line.
    Faehling M; Eckert R; Kuom S; Kamp T; Stoiber KM; Schumann C
    Oncology; 2010; 78(3-4):249-58. PubMed ID: 20523085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
    Kiyohara Y; Yamazaki N; Kishi A
    J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
    Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
    Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
    Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
    Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
    N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.
    Wojas-Krawczyk K; Krawczyk P; Mlak R; Kucharczyk T; Kowalski DM; Krzakowski M; Milanowski J
    Respiration; 2011; 82(4):341-50. PubMed ID: 21242665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib].
    Böker B; Lüders H; Grohé C
    Pneumologie; 2012 Feb; 66(2):89-95. PubMed ID: 22337328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and toxicity of erlotinib in non-small cell lung cancer treatment].
    Romero-Ventosa EY; Mucientes-Molina A; Pedrido-Reino E; Lago-Rivero N; Constenla-Caramés L; Arias-Santos I
    Farm Hosp; 2012; 36(2):68-76. PubMed ID: 21798783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
    Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
    J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
    Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
    Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
    Grossi F; Rijavec E; Dal Bello MG; Defferrari C; Brianti A; Barletta G; Genova C; Murolo C; Cosso M; Fontanini G; Boldrini L; Truini M; Pronzato P
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1407-12. PubMed ID: 22349923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
    Spigel DR; Lin M; O'Neill V; Hainsworth JD
    Cancer; 2008 Jun; 112(12):2749-55. PubMed ID: 18438878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.